Dizocilpine blocks the effects of delta sleep-inducing peptide-induced suppression of c-fos gene expression in the paraventricular nucleus of the hypothalamus in rats.
Umryukhin. P E PE; Anokhin. K V KV; Raevskii. K S KS
Key Findings
- DSIP reduces c‑fos gene expression in the paraventricular nucleus of the hypothalamus.
- Dizocilpine, an NMDA receptor antagonist, blocks the DSIP‑induced reduction of c‑fos.
- The result suggests DSIP’s effects are mediated via NMDA receptor signaling in rats.
Practical Outcomes
- The findings are mechanistic only and provide no dosing, safety, or performance guidance for humans. Biohackers cannot translate this directly into a usable protocol, though it hints that DSIP may interact with NMDA receptors, a detail that remains theoretical without human data.
Summary
In a rat study, a drug that blocks NMDA receptors (dizocilpine) stopped a sleep‑related peptide (delta sleep‑inducing peptide, DSIP) from lowering a brain activity marker (c‑fos) in a specific hypothalamic region. This shows DSIP works through NMDA pathways, but the work is purely basic science and doesn’t give any practical advice for using DSIP in people.
Abstract
The characteristics of the actions of the non-competitive blocker of NMDA receptors dizocilpine on the expression of the early c-fos gene in the paraventricular nuclei of the hypothalamus were studied in rats with different predicted susceptibilities to emotional stress in conditions of treatment with delta sleep-inducing peptide. The results showed that prior treatment with dizocilpine blocked reductions in c-fos expression induced by delta sleep peptide.
Study Information
pubmed
2004
10.1023/b:neab.0000022637.57852.e0